A method of obtaining a solution of albumin


The invention relates to the medical industry. Spend the plasma fractionation on a fractional tables with selection of raw sludge albumin. Dissolving it in pyrogen-free distilled water with subsequent brightening filtration and ultrafiltration installation Sartakon-2. Filling vials and pasteurization of the drug. The invention improves the quality of the product. 1 C.p. f-crystals, 1 Il.

The invention relates to the medical industry and can be used to obtain a solution of albumin used for intravenous hemodynamic actions and parenteral nutrition.

The main raw material for the production of albumin are different types of donor plasma prepared according to the following documents: 1. Instructions for the fractionation of blood cellular components and plasma, approved by the USSR Ministry of health 06-14/24 from 11.06.87,

2. Instructions for medical examination of donors of blood, plasma, blood cells, approved by the RF Ministry of health from 16.11.98,

3. The Ministry of health of the USSR for 155 from 12.04. 90, "On improvement of activity of the institutions of the blood service".

Albumin refers to polypeptides, the shape of the macromolecule is Sora reached by changing at different stages of fractionation of pH, alcohol concentration, temperature and ionic strength. In the process of fractionation of chemical reactions will not occur.

A method of obtaining solution of albumin, developed by research Institute of Hematology and blood transfusion MOH SSR (standard regulation for production of albumin 5, 10, and 20%), which was approved in 1987,

The method consists in the plasma fractionation on a fractional tables with selection of raw sludge albumin and dissolving it in pyrogen-free distilled water, centrifuged and clarifying filtration with subsequent filling for freezing and drying. After the stage of lyophilization dry albumin is dissolved, is subjected to sterilizing filtration, produce bottling in bottles and pasteurized.

The disadvantages of this method are the complexity of the process and the impossibility of obtaining a higher quality product. Qualitative indicators of albumin obtained by a known method, follow the target.

The invention solved the problem of improving product quality and reducing the complexity of the process.

To achieve the mentioned technical result in the proposed method, which includes stages of fractionation of the plasma on the ode with the subsequent brightening filtering, filling vials and pasteurization of the drug, the stage of freeze drying is replaced by ultrafiltration installation Sartakon-II (laundering molecules of ethanol and other low molecular weight impurities 5-fold volume of water).

This allows us to improve the quality of the obtained solution of albumin and reduce the complexity of the process.

The proposed method is illustrated by a drawing, which shows a diagram of the production of albumin (drawing). The diagram shows the fractional tables (1), refrigerated centrifuge (2), brightening filter (3), Sartakon (4), sterile filter (5), seaming machine (6), thermostat (7).

The method is as follows.

Fractionation of plasma proteins produced by the gradual separation of each fraction.

Stage 1.5 TA, TA 1.7, 1.8 TA, TA 1.9 held on the same hardware.

Plasma (stage 1.5), and then centrifugate stages TS 1.7 TS 1.8 loaded into the boiler fraction table (1). The conditions required for the selection and maturation of sediment to a specific fraction of proteins. Then the whole mixture is fed into the centrifuge and after centrifugation the precipitate is recycled, and centrifuged again supplied to the boiler (1).

Received centrifugal on stage TP 1.9 utilized, and wet the apparatus "Sartakon II (4).

The ready solution of albumin is supplied to the plant for sterile filtration (5) and filling the solution in the vials. Run caps are produced on the seaming machine (6). Thermostats (7) the finished product is pasteurized and temperature control. Example.

I. Allocation of fraction I.

The raw material was taken plasma, pre-tested for the absence of antibodies to human immunodeficiency virus (HIV), hepatitis C virus and the surface antigen of hepatitis C.

In four of the boiler, located in two fractional tables with most of the shirts (two in each), downloaded on 20 l plasma - a total of 80 l of plasma.

The plasma is cooled to +1oAnd added to it chilled in a small bath to -20oWith 96% ethyl alcohol, at the rate of 90 ml of alcohol per 1 l of plasma. By the end of the deposition temperature of the mixture drops to -3oC. after the addition of alcohol the mixture was stirred 2 h and then left for two hours. In these conditions in the sediment falls fraction 1 plasma proteins, containing mainly fibrinogen. The precipitate is separated on stakanchikov refrigerated centrifuge Sorvall RC 3C Plus at t = -3oC and 3000 rpm for 30 minutes the Precipitate is not used II. The allocation fraction II+III.

Centrifugal I the temperature centrifugate reaches -5 -6oWith buffer 1 pH brought to the 5.8 to 5.9. Then, at the rate of 150 ml/l of centrifugate I, is added 96% ethanol cooled to -20oWith a speed of 15 ml/min. the Precipitate Matures 12 o'clock the sludge Separation is carried out on the centrifuge Sorvall RC 3C Plus at a temperature of -6oWith and 3200 rpm for 30 minutes the Precipitate is not used.

III. The allocation fraction IV.

Centrifugal II is placed in the boiler fraction boiler and cooled to a temperature of -7oBack To him with the speed of 15 ml/min is added 96% ethanol, pre-cooled to a temperature of -20oWith a rate of 450 ml/l of centrifugate II. After adding the alcohol mixture is left to ripen the sediment at 12 hours the Precipitate is separated by centrifuge Sorvall RC 3C Plus at a temperature of -7oWith and 3500 rpm for 45 minutes the Precipitate is not used.

IV. The allocation fraction V (albumin).

Before selecting the fraction V, centrifugal III is subjected to clarifying filtration using pressure tank and filter with pores of 0.8 to+0.65m in the boiler fraction buffet at a temperature of -7oC. After filtration of the intake samples for determination of pH. Then, using buffer 2 pH is brought to 4.7 and 4.9. For completeness of precipitation of albumin mixture remains in the Fugue Sorvall RC 3C Plus at a temperature of -7oWith and 3700 rpm for 60 min. the Supernatant liquid is not used. The residue is weighed and stored at -20oWith no more than 30 days. Thus, there is an accumulation of sediment.

V. Processing of raw sludge albumin. For additional purification from the globulin precipitate albumin dissolved in pyrogen-free distilled water, pre-cooled to +5oSince, in the ratio of 1:3. The dissolution is effected in the boiler, placed in fractional table, with constant stirring at a temperature of +5oC for 2 hours While albumin is dissolved and volatile impurities precipitate. The sludge separation of volatile impurities is carried out using a clarifying filtration on filters with pores of 0.8 to+0.65m

VI. Ultrafiltration of a solution of albumin.

The release of albumin from alcohol is carried out on the device "Sartakon II in stainless steel tanks at a temperature of +4 +6oC. one volume of a solution of albumin is added to one volume of pyrogen-free distilled water and starts ultrafiltration at an input pressure of 2 bar, the output of 1.3-1.5 bar. In descending order solution is added to five volumes of pyrogen-free distilled water. By albumin and adjust the pH of the solution (pH should be 6.5 to 7.2).

VII. Getting the finished product.

Prepared 10% solution of albumin is transmitted to sterilizing filtration. Sterilizing filtration and bottling albumin vials is performed under sterile conditions in a laminar box with a filter with pores of 0.45+0,2m and pressure tank. Bottles youprivate rubber plugs and obkatyvalisj aluminum caps. The entire series of the preparation is heated in a thermostat at a temperature of 601oC for 10 h to inactivate the virus of infectious hepatitis (pasteurization). After pasteurization, the product is aged at a temperature of +37oWith in 2 weeks (stabilization of proteins), and then is subjected to all kinds of control, labeling and packaging.

There was obtained a solution of albumin with the following parameters (analytical passport attached).

The inventive method allows to obtain the solution of albumin with higher quality characteristics (increased albumin levels, reduced color content of the polymers, sodium ion and potassium ion). Greatly reduced the complexity of the process, i.e., reduced production space, reduced energy consumption, easier conditions trusia.


1. A method of obtaining a solution of albumin, which includes stages of fractionation of the plasma on a fractional tables with selection of raw sludge albumin and dissolving it in pyrogen-free distilled water followed by filtration, filling into vials and pasteurization of the drug, wherein the stage after clarifying filtration conduct ultrafiltration.

2. The method according to p. 1, wherein the ultrafiltration is carried out at the installation Sartakon-II.


Same patents:

The invention relates to cyclic bind to the integrin peptide length 7-11 amino acid residues that includes the amino acid sequence (RKK)

The invention relates to a new group of individual chemical compounds - cyclic amino compounds represented by the following formula:

< / BR>
where R1represents a phenyl group which may be optionally substituted by at least one Deputy, which represents a halogen atom; R2represents a C1-C8aliphatic acyl group or (C1-C4alkoxy) carbonyl group; and R3represents a saturated cyclic amino group which has from 2 to 8 carbon atoms in one or more cycles, with the highest nitrogen cycle has from 3 to 7 atoms in the cycle, and the specified saturated cyclic amino group substituted by a group having the formula-S-S-R4where R4and X have the meanings as defined below, and the said saturated cyclic amino group attached via its cyclic nitrogen atom adjacent to the carbon atom that is attached to the substituents R2and R1; R4represents a phenyl group which may be optionally substituted by at least one Deputy, selected IGP and nitro groups; WITH1-C6alkyl group which may be optionally substituted by at least one Deputy, selected from the group consisting of amino groups, carboxyl groups, (C1-C4alkoxy)carbonyl groups, substituents having the formula-NH-A1(where a1represents an-amino acid residue), and substituents having the formula-CO-AND2(where a2represents an-amino acid residue); or (C3-C8cycloalkyl group, and X represents a sulfur atom, sulfinol group or sulfonyloxy group, and the above-mentioned cyclic aminecontaining group may be optionally additionally substituted by a group having the formula = CR5R6where R5and R6are the same or different, and each independently represents a hydrogen atom, a carboxyl group, (C1-C4alkoxy)carbonyl group, karbamoilnuyu group, (C1-C4alkyl) karbamoilnuyu group or di-(C1-C4alkyl)karbamoilnuyu group; or their pharmacologically acceptable salts, pharmaceutical composition having inhibitory action in Rel is the prevention of disease, selected from the group consisting of embolism and thrombosis in a warm-blooded animal

The invention relates to animal breeding and fur farming

The invention relates to derivatives of cyclic peptides of General formula I cyclo (Arg-X-Asp-R1), where X represents Gly, Ala; R1- the remainder of the formula II

< / BR>
where R2, R3denote H; R4= R5- Ar or R4= Ar, where R5- alkylen (C1-C6); Ar is unsubstituted phenyl; or R4= A, where A = (C1-C6)alkyl, and, if you have in mind remains optically active amino acids, these compounds include D-and L-forms, and their salts, method of production thereof, pharmaceutical composition having the ability to inhibit integrin containing as active ingredient a compound of the formula I

-converting enzyme)" target="_blank">

The invention relates to novel ortho-sulfonamidophenylhydrazine heteroaryl hydroxamic acids of the formula

< / BR>
where W and X are both carbon, T is nitrogen, U represents CR1where R1represents hydrogen, or alkyl containing 1-8 carbon atoms, R represents-N(CH2R5)-SO2Z, Q represents -(C=O)-NHOH, with

< / BR>
is a benzene ring, or is a heteroaryl ring of 5 to 6 atoms in the cycle, which may contain 0-2 heteroatoms selected from nitrogen, oxygen and sulfur, in addition to the heteroatom of nitrogen, denoted as W, where benzene or heteroaryl ring may optionally contain one or two substituent R1where permissible; Z is phenyl, which is optionally substituted by phenyl, alkyl with 1-8 carbon atoms, or a group OR2; R1represents halogen, alkyl with 1-8 carbon atoms, alkenyl with 2-6 carbon atoms, perfluoroalkyl from 1 to 4 carbon atoms, phenyl, optionally substituted by 1-2 groups OR2group-NO2group -(CH2)nZ, where Z is a phenyl which allows an alkyl with 1-8 carbon atoms, phenyl, optionally substituted with halogen, or heteroaryl radical containing 5 to 6 atoms in the cycle, including 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; R5represents hydrogen, alkyl with 1-8 carbon atoms, phenyl, or heteroaryl containing 5 to 6 atoms in the cycle, including 1-2 heteroatoms selected from nitrogen, oxygen and sulfur; or their pharmaceutically acceptable salts

The invention relates to derivatives of N-(4-carbamimidoyl) glycinamide formula (I), where E denotes hydrogen or HE, Q denotes hydrogen or alkyl, R is aryl, cycloalkyl or alkyl substituted radicals R1, R2, R3, R1denotes hydrogen, COOH, COO-alkyl or aryl, R2denotes hydrogen, aryl, cycloalkyl or heteroaryl, R3denotes hydrogen, aryl or HE (in any position other thanposition relative to the nitrogen atom is attached to an alkyl group R) or optional substituted by an amino group, three of the radicals X1-X4denote the group of C(Ra), C(Rb) or C(Rc), and the fourth represents C(Rd), Ra-Rddenote H, HE, NO2dialkylamino, halogen, alkyl, alkoxy, aryloxy, aralkylated, heteroarylboronic, geterotsiklicheskikh, COOH, COO-alkyl, NH-SO2-alkyl, NH-SO2-aryl, two adjacent groups Ra-Rbdenote alkylenedioxy, G1and G2denote hydrogen, HE, the invention relates to intermediate compounds of the formula (IV), (V), (VI) used in the methods of making compounds of formula (I), and are in взаимодействCN, the nitrile of formula (IV) is transformed into amidinopropane C(N-G1)NH-G2
The invention relates to medicine, specifically to pharmaceutical compositions comprising as active ingredient indapamide, and may find application in the treatment of hypertension and to prevent the delay of sodium and water in the body in chronic heart failure

The invention relates to chemical-pharmaceutical industry, associated with obtaining water-soluble drugs acetylsalicylic acid (ASA) related to non-steroidal anti-inflammatory drugs and possessing antithrombotic, analgesic, anti-inflammatory and antipyretic action, the main of which is the influence on the adhesion and aggregation of platelets [Bokarev, I. N., A. Ivlev I
The invention relates to medicine, namely to ophthalmology and for the treatment of herpetic eye lesions

The invention relates to medicine, namely to therapy, and can be used in the treatment of malnutrition

The invention relates to medicine, namely to the production of medical biological preparations, and can be used to obtain albumin from unused, ballast albuminaemia fractions

The invention relates to medicine, namely to a method for albumin

The invention relates to medicine, namely to Oncology, clinical immunology, and can be advantageously used for the treatment of cancer

The invention relates to medicine, namely to otolaryngology and Allergy

FIELD: cosmetology.

SUBSTANCE: human serum albumin (HAS) should be obtained out of transgenic animals, not out of men, to be mixed with corresponding carrier and/or adjuvant. HAS should be obtained out of cattle, sheep, swine, horse, rodents or goat. HAS should be obtained either out of milk or blood of transgenic animals, not out of men. HAS should be obtained out of an egg of transgenic poultry. Cosmetic composition should be obtained due to similar technique. Cosmetic composition is either lotion, cream, gel or oil to be applied in case of cosmetic treating wrinkles, scars and burn wounds. The present innovation enables to cheapen the product at keeping its high activity.

EFFECT: higher efficiency of application.

19 cl

FIELD: organic chemistry, amino acids.

SUBSTANCE: invention proposes agonists of somatostatin of the formula (I): X-A1-cyclo-(D-Cys-A3-A4-Lys-A6-A7)-A8-Y or its pharmaceutically acceptable salt wherein X represents hydrogen atom (H); A1 represents L-Cpa, L-Phe, L-Trp or L-Nal; A3 represents L-3-Pal or L-4-Pal; A4 represents D-Trp; A6 represents -NH-(CHR1)n-CO- wherein n = 2, 3 or 4; A7 represents L- or D-Cys; A8 represents D- or L-isomer of amino acid taken among the group consisting of Nal, Phe, Cpa and Trp; Y represents NH2; R1 represents hydrogen atom (H), and Cys in A3 is bound by disulfide bong in A wherein this disulfide bond is formed by thiol groups of each Cys residue.

EFFECT: valuable biological properties of compounds.

9 cl, 2 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with the ways of extracorporal detoxication and treatment of hepatic failure. The method should be implemented due to introducing albumin-containing solution through a catheter into abdominal cavity at concentration of 30-40 g/l as dialyzing liquid for 2-4 h. This solution should be purified through "Artificial kidney" apparatus, coal sorbent and anion-exchange resin. Perfusion rate of albumin-containing solution in the course of its purification corresponds to 20-30 ml/min. Detoxication cycle with the help of albumin followed by its deligandization should be repeated many times. The innovation provides optimal mode of perfusion and, thus, high rate of toxins elimination through patient's peritoneum and excludes the necessity in applying anticoagulants and expensive "MARS" system.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: pharmaceutical industry, in particular drug containing human recombinant alpha-2 interferon.

SUBSTANCE: claimed prolonged solution contains human recombinant alpha-2 interferon, citric acid, boric acid, sodium tetraborate, unithiol, human serum albumin, sodium chloride, sodium carboxymethylcellulose and purified water. Preparation of present invention has wide spectrum of therapeutic application.

EFFECT: drug of high specific antiviral and antimicrobial activity without side effects.

1 tbl, 3 ex